| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_859d7efc6733b4930e72003b3d96b82a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04 |
| filingDate |
2021-12-16^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cb843c2a723136064f22536ce004c97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0060bca353d41d84742152023068ea20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9e449332037bf81f433424db2114a70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54e5f93016c84acd5b50534f807ce876 |
| publicationDate |
2022-06-23^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022133078-A1 |
| titleOfInvention |
Dosage forms of tie-2 activators |
| abstract |
Disclosed herein are compounds and compositions effective for modulation of Tie-2 and HPTP-beta. The compounds can provide effective therapy for vascular disease, including those associated with inflammation and leakage, pathologic neovascularization, and angiogenesis. |
| priorityDate |
2020-12-18^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |